Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia

被引：37
作者：
Carneiro, Benedito A. [1 ,2 ,3 ]
Kaplan, Jason B. [1 ,2 ,3 ]
Altman, Jessica K. [1 ,2 ,3 ]
Giles, Francis J. [1 ,2 ,3 ]
Platanias, Leonidas C. [1 ,2 ,3 ,4 ]
机构：
[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Div Hematol & Oncol, Chicago, IL 60611 USA
[3] Northwestern Univ, Feinberg Sch Med, Northwestern Med Dev Therapeut Inst, Chicago, IL 60611 USA
[4] Jesse Brown VA Med Ctr, Div Hematol Oncol, Dept Med, Chicago, IL USA
来源：
CANCER BIOLOGY & THERAPY | 2015年 / 16卷 / 05期
基金：
美国国家卫生研究院;
关键词：
Acute myeloid leukemia; Akt; AML; MAPK; mTOR; PI3K; targeted therapy; ACUTE MYELOGENOUS LEUKEMIA; REFRACTORY HEMATOLOGIC MALIGNANCIES; ACUTE LYMPHOBLASTIC-LEUKEMIA; SMALL-MOLECULE INHIBITORS; NF-KAPPA-B; AKT-INHIBITOR; PHASE-I; CELL-PROLIFERATION; MAMMALIAN TARGET; KINASE INHIBITOR;
D O I：
10.1080/15384047.2015.1026510
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
An accumulating understanding of the complex pathogenesis of acute myeloid leukemia (AML) continues to lead to promising therapeutic approaches. Among the key aberrant intracellular signaling pathways involved in AML, the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) axis is of major interest. This axis modulates a wide array of critical cellular functions, including proliferation, metabolism, and survival. Pharmacologic inhibitors of components of this pathway have been developed over the past decade, but none has an established role in the treatment of AML. This review will discuss the preclinical data and clinical results driving ongoing attempts to exploit the PI3K/AKT/mTOR pathway in patients with AML and address issues related to negative feedback loops that account for leukemic cell survival. Targeting the PI3K/AKT/mTOR pathway is of high interest for the treatment of AML, but combination therapies with other targeted agents may be needed to block negative feedback loops in leukemia cells.
引用
收藏
页码：648 / 656
页数：9
相关论文
共 112 条
[21]   Use of the Pharmacological Inhibitor BX795 to Study the Regulation and Physiological Roles of TBK1 and IκB Kinase ε A DISTINCT UPSTREAM KINASE MEDIATES SER-172 PHOSPHORYLATION AND ACTIVATION [J].
Clark, Kristopher ;
Plater, Lorna ;
Peggie, Mark ;
Cohen, Philip .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (21) :14136-14146
[22]   Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery [J].
Datta, SR ;
Dudek, H ;
Tao, X ;
Masters, S ;
Fu, HA ;
Gotoh, Y ;
Greenberg, ME .
CELL, 1997, 91 (02) :231-241
[23]   Discovery of 5-( 2-( Phenylamino) pyrimidin-4-yl) thiazol2( 3H)- one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation [J].
Diab, Sarah ;
Teo, Theodosia ;
Kumarasiri, Malika ;
Li, Peng ;
Yu, Mingfeng ;
Lam, Frankie ;
Basnet, Sunita K. C. ;
Sykes, Matthew J. ;
Albrecht, Hugo ;
Milne, Robert ;
Wang, Shudong .
CHEMMEDCHEM, 2014, 9 (05) :962-972
[24]   Glycogen synthase kinase 3β regulates cyclin D1 proteolysis and subcellular localization [J].
Diehl, JA ;
Cheng, MG ;
Roussel, MF ;
Sherr, CJ .
GENES & DEVELOPMENT, 1998, 12 (22) :3499-3511
[25]   Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007 [J].
Dores, Graca M. ;
Devesa, Susan S. ;
Curtis, Rochelle E. ;
Linet, Martha S. ;
Morton, Lindsay M. .
BLOOD, 2012, 119 (01) :34-43
[26]   Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer [J].
Duncan, James S. ;
Whittle, Martin C. ;
Nakamura, Kazuhiro ;
Abell, Amy N. ;
Midland, Alicia A. ;
Zawistowski, Jon S. ;
Johnson, Nancy L. ;
Granger, Deborah A. ;
Jordan, Nicole Vincent ;
Darr, David B. ;
Usary, Jerry ;
Kuan, Pei-Fen ;
Smalley, David M. ;
Major, Ben ;
He, Xiaping ;
Hoadley, Katherine A. ;
Zhou, Bing ;
Sharpless, Norman E. ;
Perou, Charles M. ;
Kim, William Y. ;
Gomez, Shawn M. ;
Chen, Xin ;
Jin, Jian ;
Frye, Stephen V. ;
Earp, H. Shelton ;
Graves, Lee M. ;
Johnson, Gary L. .
CELL, 2012, 149 (02) :307-321
[27]   Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1 [J].
Feldman, RI ;
Wu, JM ;
Polokoff, MA ;
Kochanny, MJ ;
Dinter, H ;
Zhu, DG ;
Biroc, SL ;
Alicke, B ;
Bryant, J ;
Yuan, SD ;
Buckman, BO ;
Lentz, D ;
Ferrer, M ;
Whitlow, M ;
Adler, M ;
Finster, S ;
Chang, Z ;
Arnaiz, DO .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (20) :19867-19874
[28]   A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms [J].
Figg, William D. ;
Monga, Manish ;
Headlee, Donna ;
Shah, Avni ;
Chau, Cindy H. ;
Peer, Cody ;
Messman, Richard ;
Elsayed, Yusri A. ;
Murgo, Anthony J. ;
Melillo, Giovanni ;
Ryan, Qin C. ;
Kalnitskiy, Mikhail ;
Senderowicz, Adrian M. ;
Hollingshead, Melinda ;
Arbuck, Susan G. ;
Sausville, Edward A. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) :955-967
[29]   Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model [J].
Floc'h, Nicolas ;
Kinkade, Carolyn Waugh ;
Kobayashi, Takashi ;
Aytes, Alvaro ;
Lefebvre, Celine ;
Mitrofanova, Antonina ;
Cardiff, Robert D. ;
Califano, Andrea ;
Shen, Michael M. ;
Abate-Shen, Cory .
CANCER RESEARCH, 2012, 72 (17) :4483-4493
[30]   Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival [J].
Flynn, P ;
Wong, M ;
Zavar, M ;
Dean, NM ;
Stokoe, D .
CURRENT BIOLOGY, 2000, 10 (22) :1439-1442
12345678910